BACKGROUND G protein-mediated signal transduction plays a key role in pathways of metastasis. A C/T polymorphism (dbSNP rs5443) at position 825 of the GNB3 gene has been described. Previous studies demonstrated an association between the GNB3 C825T genotype and different cancer entities. PATIENTS AND METHODS In this report genotyping for this marker was performed in 235 prostate cancer patients and 111 healthy control subjects. Clinical follow-up data were available for a subset of 197 patients. RESULTS Neither significant evidence for differences in genotype distributions between the prostate cancer cases and controls (odds ratio CT/TT=0.94, 95% CI 0.58-1.51, p=.82) nor evidence for genotype differences in e.g. progression-free survival in the subset of patients was observable (hazard ratio CT/TT=0.77, 95% CI 0.44-1.37, p=.38). Similar results were obtained in the subgroup of patients with primary tumor stage ≤ pT2 N0 M0 undergoing radical prostatectomy. CONCLUSION Our data do not support an association between prostate cancer and the genotype of the GNB3 C825T polymorphism. This finding might either indicate a much smaller genetic effect undetectable with the given sample size or a possible hormone dependence of the disease superimposed on the potential effect of the GNB3 C825T genotype.
CITATION STYLE
Eisenhardt, A., Scherag, A., Kempin, M., Jöckel, K. H., & Rübben, H. (2011). [Genotype of the GNB3 C825T polymorphism, A risk factor for the development and course of prostate cancer?]. Der Urologe. Ausg. A, 50(9), 1137–42. https://doi.org/10.1007/s00120-011-2621-8
Mendeley helps you to discover research relevant for your work.